cbdMD, Inc. (YCBD)

NYSE: YCBD · Perfumes, Cosmetics & Other Toilet Preparations · Charlotte, NC · filing with the SEC since 2015

Full chart Alerts Compare

Grade3.3

◀ Past 1.9● Present 3.3▶ Future 4.5

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of cbdMD, Inc.

Nine metrics read from its own filings, by tense

Headline grade

3.3/10

◀ Past1.930% of the headline

● Present3.340% of the headline

▶ Future4.530% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.9/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

1.4/10

Has it survived what it has been through?

5 warning events since 2017; the latest 2025-01-03.

weight 33% of this tense · 14th percentile among 18 sector filers · read for itself

From the record

cbdMD, Inc.'s filings since 2017 show 5 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2025-01-03); a warning not to rely on past financial statements (8-K item 4.02, the latest 2019-04-18) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

3.1/10

What has it actually done, year after year?

+28.3% a year over 10 filed years; profitable in 2 of 10.

weight 45% of this tense · 31st percentile among 16 sector filers · read for its customers

From the record

cbdMD, Inc.'s 10 filed years say what it did: revenue went from $2 million in fiscal 2016 to $19 million in fiscal 2025, up 28.3% a year; it rose in 4 of 9 years; the deepest fall was 90% from fiscal 2017 to fiscal 2018; net income was positive in 2 of 10 of those years (its annual reports).

What it rests on

revenue growth over the filed span28.3%top 28% of its family
the share of years revenue rosebottom 16% of its family
the share of filed years with a profitbottom 22% of its family
the deepest fall from a revenue peak89.7%bottom 16% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

0.3/10

How has it treated the people who own it?

SI estimate 0.3/10, confidence 35 of 100 (one part).

weight 22% of this tense · 3rd percentile among 16 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the bottom 3% of 16 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 16 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: cbdMD, Inc.'s shareholder treatment is put at 0.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 3% of 16 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.3/1040% of the headline grade · 3 of 3 filed

Financial health

as filed

4.4/10

Is it financially healthy right now?

ROE -28%: lost 28¢ per shareholder dollar. Leverage 31%: owes 31¢ per asset dollar.

weight 45% of this tense · 44th percentile among 17 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-09-30, cbdMD, Inc. lost about 28 cents for every dollar of shareholders' money, and gross profitability: its products earned about 115 cents per dollar of everything the company owns. Leverage: it owed about 31 cents per dollar of assets, and net share issuance: its share count grew 646.2% over the year (the filed statements).

What it rests on

what it owes per dollar of assetstop 38% of its family
return on equitybottom 21% of its family
gross profit against assetstop 9% of its family
the share count against the year beforebottom 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

1.6/10

How strong is its position in its industry?

bottom 16% of 17 in its family; net margin -10.6%.

weight 33% of this tense · 16th percentile among 17 sector filers · read for its customers

From the record

cbdMD, Inc.'s standing among 17 graded names in its industry family: revenue of $19 million in fiscal 2025 ranks in the bottom 23% by size; a net margin of -10.6% ranks in the bottom 21%; revenue growth of -18.5% a year over the last 3 filed years ranks in the bottom 3% (its annual reports).

What it rests on

revenue against the family$19.2Mbottom 23% of its family
net margin-10.6%bottom 21% of its family
three-year revenue growth-18.5%bottom 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

3.8/10

What are the people in charge doing?

bottom 38% of 10 in its family for leadership; chief executive since 2023.

weight 22% of this tense · 38th percentile among 10 sector filers · read for its shareholders

From the record

cbdMD, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Kennedy, Thomas Ronan (CEO and CFO, as filed), filing under that title since 2023-05-05, 3.5 years (bottom 39% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (bottom 39%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 7 people in charge now (bottom 36%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge4 in three years among 7 peoplebottom 36% of its family
the median years the people in charge have filed6.1 yearsbottom 39% of its family
the chief executive's years on the record3.5 yearsbottom 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.5/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed

4.7/10

How much room does it have to grow?

bottom 47% of 17 in its family for room to expand.

weight 45% of this tense · 47th percentile among 17 sector filers · read for itself

From the record

cbdMD, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $2 million against no long-term debt tagged leaves 21.7% of its assets as net cash, top 23% of its family; cash from operations less capital spending is -8.5% of revenue (bottom 21%); a gross margin of 62.4% (bottom 44%) (its annual report).

What it rests on

cash less debt against assets21.7%top 23% of its family
cash from operations less capital spending against revenue-8.5%bottom 21% of its family
gross margin62.4%bottom 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

0.9/10

What could actually drive growth from here?

bottom 9% of 16 in its family for growth drivers.

weight 33% of this tense · 9th percentile among 16 sector filers · read for its customers

From the record

cbdMD, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -18.5% a year over the last three filed years against 28.3% over all 10, slowing (bottom 3% of its family); the newest year grew -1.5% (bottom 22%); capital spending grew -35.6% a year (bottom 3%) (its annual reports). cbdMD, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

three-year growth against the whole span-46.8 points a yearbottom 3% of its family
the newest year's revenue growth-1.5%bottom 22% of its family
three-year growth of capital spending-35.6%bottom 3% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed

9.3/10

Did its newest year beat what its own record pointed to?

top 7% of 16 in its family for expectations against reality.

weight 22% of this tense · 93rd percentile among 16 sector filers · read for its shareholders

From the record

cbdMD, Inc.'s newest year against its own record: revenue of $19 million in fiscal 2025 came in 32.8% above the $14 million its prior three years' pace pointed to (top 3% of its family); net income of $2 million against a prior three-year average of $32 million (top 9%); a net margin of -10.6% against losses larger than its revenue before (top 9%) (its annual reports).

What it rests on

revenue against the prior three years' pace32.8%top 3% of its family
net income against the prior three years' average+94%top 9% of its family
net margin against its prior average+93.3 pointstop 9% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton YCBD · research, not advice